Franklin Street Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Franklin Street Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,400	Closed	-$228K	–	134
2020 Q1	$228K	Hold	5,400	–	–	0.03%	120
2019 Q4	$231K	Buy	+5,400	New	+$235K	0.03%	138
2017 Q4	–	Sell	-5,400	Closed	-$203K	–	167
2017 Q3	$203K	Buy	+5,400	New	+$176K	0.03%	145

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Franklin Street Advisors's ACAD Position: Q2 2020 in Review

Franklin Street Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 5,400 shares — an estimated $228K sold.

Franklin Street Advisors first reported a position in ACAD in Q3 2017 and held it in 3 quarters. The position peaked at $231K in Q4 2019. 298 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

Franklin Street Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Franklin Street Advisors sold 5,400 Acadia Pharmaceuticals shares in Q2 2020, an estimated $228K.
Franklin Street Advisors first reported a position in Acadia Pharmaceuticals in Q3 2017 and held it in 3 quarters.
Franklin Street Advisors's Acadia Pharmaceuticals position peaked at $231K in Q4 2019.
298 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on Franklin Street Advisors's 13F filing for Q2 2020, filed 6 Aug 2020.